Efficacy and safety of Xuebijing injection and its influence on immunomodulation in acute exacerbations of chronic obstructive pulmonary disease: study protocol for a randomized controlled trial

Abstract

Background Acute exacerbation of chronic obstructive pulmonary disease (AECOPD) is the leading cause of mortality in chronic obstructive pulmonary disease (COPD). Traditional Chinese medicine (TCM) has been widely used in Asia as an adjunct treatment for AECOPD to improve the patients’ symptoms. Xuebijing (XBJ) injection is one of the major herbal medicines used in TCM. Previous small-sample clinical trials have proven its efficacy and safety in the treatment of AECOPD; however, the current data on XBJ as an adjunct therapy are insufficient. The present study will be a multi-center randomized clinical trial (RCT) to evaluate the efficacy and safety of XBJ injection in AECOPD and explore its influence on the immune function based on the altered levels of T cells. Methods This study will be a prospective, randomized, placebo-controlled, blinded, multi-center trial. A total of 300 eligible patients will be randomly assigned to the treatment or placebo control group in a 1:1 ratio using a central randomization system. The treatment group will receive routine medication plus XBJ injection, and the control group will receive routine medication plus 0.9% NaCl injection. The patients will receive the corresponding treatment for 5 days starting within 24 h of enrollment. The primary outcome, the of rate endotracheal intubation, will be evaluated on day 28 after treatment. The secondary outcomes will include changes in immune and inflammatory indicators, respiratory support, mortality rate after 28 days, blood gas analysis, improvement in Acute physiology and chronic health evaluation (APACHE) II scores and clinical symptoms, and the length and cost of intensive care unit stay and hospitalization. The safety of the interventions will be assessed throughout the trial. Discussion This is the first and largest randomized, controlled, blinded trial that evaluates the efficacy of XBJ injection as adjuvant therapy for AECOPD. The results of this trial will provide valuable clinical evidence for recommendations on the management of the disease and identify the underlying mechanisms. Trial registration ClinicalTrials.gov, NCT02937974 . Registered on 13 October 2016. Chinese clinical trial registry, ChiCTR-IPR-17011667. Registered on 15 June 2017. Electronic supplementary material The online version of this article (10.1186/s13063-019-3204-z) contains supplementary material, which is available to authorized users.

Effect of Yifei-Huoxue Decoction Combined with Tiotropium on Inflammatory Cytokine Levels, Pulmonary Function, and Quality of Life in Patients with Chronic Obstructive Pulmonary Disease

“…COPD is a common and frequently encountered respiratory disease and presents progressive development due to airflow limitation. COPD, with slow onset and long duration, seriously affects patients' labor ability and quality of life and brings a huge social and economic burden for the patients with the progressive decline of pulmonary function [ 14 – 16 ]. COPD is irreversible, and the main treatment principles are controlling disease development, enhancing lung function, and improving quality of life.…”

Assessing Treatment Success or Failure as an Outcome in Randomised Clinical Trials of COPD Exacerbations. A Meta-Epidemiological Study

“…Thirty-four RCTs included 45 descriptive instruments [ 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 ]. All but three trials were deemed to be at high risk of methodological bias.…”

Chinese herbal injections for coronavirus disease 2019 (COVID-19): A narrative review

“…[ 21 ] Recent clinical randomized controlled trial showed that XueBiJing injection was effective and safe in the treatment of acute exacerbation of chronic obstructive pulmonary disease (AECOPD). [ 22 ] It showed protective potential against lung injury in patients who undergo cardiopulmonary bypass surgery due to downregulation of inflammatory mediators, reduction in neutrophil infiltration, and upregulation of IL-10. [ 23 ] Moreover, XueBiJing injection (Tianjin Chase Sun Pharmaceutical Co., Tianjin, China) with the dosage of 100 mL (0.1 g/mL) in normal saline 100 mL (every 12 hours, intravenous drip) versus placebo could also significantly improve the primary endpoint of the pneumonia severity index, the secondary clinical outcomes of mortality, and the duration of mechanical ventilation and intensive care unit (ICU) stay in critically ill patients with severe pneumonia.…”